Brain Scientific Inc. (BRSF) Joins Forces with Jel
Post# of 129
(Total Views: 170)
Posted On: 04/23/2021 4:28:15 PM
Brain Scientific Inc. (BRSF) Joins Forces with JelikaLite to Reduce Symptoms of Autism
- BRSF and JelikaLite have joined forces in a clinical trial for reducing autism symptoms in children
- JelikaLite uses PRM therapy to reduce autism symptoms
- BRSF sees this as an important step forward in wider adoption of affordable, accessible EEG systems
The neurology-focused medical device and software company Brain Scientific (OTCQB: BRSF) announced on March 16, 2021, it is collaborating with JelikaLite in a clinical trial. The clinical trial, which began in March 2021, is designed to potentially uncover new treatment options to reduce autism symptoms in children. The trial has 30 participants from two New York City locations.
JelikaLite was launched by medical researchers and practitioners specializing in psychology, neurology and phototherapy. The company has developed an innovative solution to potentially reduce autism symptoms and is developing a home-based system that combines a therapeutic wearable device called Cognilum(TM) with an AI-personalized platform. The goal is to create personalized recommendations for each child’s individual treatment through data collection, analysis and reporting, leading to gains in communication and daily living skills.
Cognilum delivers treatments through transcranial photobiomodulation, also known as PBM therapy. Using an innovative red and near-infrared light treatment, cellular function is stimulated. This type of therapy is already being used for wound healing, tissue regeneration, inflammation, pain management, hair restoration, skin rejuvenation and restoration of normal cellular function. It is currently being studied for multiple neurological disorders, including but not limited to traumatic brain injury, post-traumatic stress disorder, depression, anxiety and opioid addiction.
Through the clinical trial, children diagnosed with autism will receive brain treatments through Cognilum while BRSF’s next-generation NeuroEEG monitors brain activity. BRSF was recently awarded FDA clearance (https://nnw.fm/XukGg) for its new version of the NeuroCap, which offers expanded size ranges for children.
There are approximately 1.5 million children in the United States who have autism, which is one of the fastest-growing developmental disorders in this country. The lifetime costs of autism range anywhere from $1.4 to $2.2 million (https://nnw.fm/oIYsJ).
“We are delighted to begin this collaboration with JelikaLite,” said Irina Nazarova, director of marketing at BRSF. “Our Neuro EEG solutions have a wide range of applications, and helping to monitor children with autism to improve their well-being would be an important step towards a wider adoption of affordable and accessible EEG systems like ours.”
For more information, visit the company’s website at www.BrainScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://nnw.fm/BRSF
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- BRSF and JelikaLite have joined forces in a clinical trial for reducing autism symptoms in children
- JelikaLite uses PRM therapy to reduce autism symptoms
- BRSF sees this as an important step forward in wider adoption of affordable, accessible EEG systems
The neurology-focused medical device and software company Brain Scientific (OTCQB: BRSF) announced on March 16, 2021, it is collaborating with JelikaLite in a clinical trial. The clinical trial, which began in March 2021, is designed to potentially uncover new treatment options to reduce autism symptoms in children. The trial has 30 participants from two New York City locations.
JelikaLite was launched by medical researchers and practitioners specializing in psychology, neurology and phototherapy. The company has developed an innovative solution to potentially reduce autism symptoms and is developing a home-based system that combines a therapeutic wearable device called Cognilum(TM) with an AI-personalized platform. The goal is to create personalized recommendations for each child’s individual treatment through data collection, analysis and reporting, leading to gains in communication and daily living skills.
Cognilum delivers treatments through transcranial photobiomodulation, also known as PBM therapy. Using an innovative red and near-infrared light treatment, cellular function is stimulated. This type of therapy is already being used for wound healing, tissue regeneration, inflammation, pain management, hair restoration, skin rejuvenation and restoration of normal cellular function. It is currently being studied for multiple neurological disorders, including but not limited to traumatic brain injury, post-traumatic stress disorder, depression, anxiety and opioid addiction.
Through the clinical trial, children diagnosed with autism will receive brain treatments through Cognilum while BRSF’s next-generation NeuroEEG monitors brain activity. BRSF was recently awarded FDA clearance (https://nnw.fm/XukGg) for its new version of the NeuroCap, which offers expanded size ranges for children.
There are approximately 1.5 million children in the United States who have autism, which is one of the fastest-growing developmental disorders in this country. The lifetime costs of autism range anywhere from $1.4 to $2.2 million (https://nnw.fm/oIYsJ).
“We are delighted to begin this collaboration with JelikaLite,” said Irina Nazarova, director of marketing at BRSF. “Our Neuro EEG solutions have a wide range of applications, and helping to monitor children with autism to improve their well-being would be an important step towards a wider adoption of affordable and accessible EEG systems like ours.”
For more information, visit the company’s website at www.BrainScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://nnw.fm/BRSF
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)